27.03.2013 - British Clinigen Group broadens its cancer support therapy focus with the acquisition of Novartis' cardioprotective agent Cardioxane.
The UK specialist for cancer support therapy has licenced Cardioxane (dexrazoxane) from Novartis for US$33m in cash, payable in two tranches. Under the terms of the agreement, Clinigen will lead manufacturing, registration, distribution, and commercialisation in all countries where marketing authorisations for the cardioprotectant have been already granted.
Cardioxane is used to prevent chronic cumulative cardiotoxicity of anthracycline chemotherapy such as doxorubicin or in advanced and metastatic adult breast cancer. The company said it believes there is an opportunity to revitalise Cardioxane, which has no direct licensed competition in the anthracycline therapy cardioprotection space, by establishing new commercialisation, market and indication strategies over the next five years.
Historic revenues for Cardioxane have been about US$11-12m per year with Latin America, where Clinigen wants to expand, as a strong market. Cardioxane is the third addition to Clinigen's Specialty Pharmaceuticals business. It complements Foscavir, an anti-viral compound licenced from AstraZeneca, which fights CMV infections in leukemia patients undergoing bone marrow transplantation. Recently, the British company licensed Vibativ from Theravance. It fights hospital-acquired MRSA infections.
Cardioxane was initially licensed in 1992. Subsequently, Novartis bought the product as part of the 2006 acquisition of Chiron. The compound is currently licensed for sale in 43 markets around the world, including 18 in Latin America. Within the European Union, Cardioxane underwent a revision to its label in 2011, restricting its licensed use to advanced and/or metastatic breast cancer. The change brought the EU label in line with the dexrazoxane indication that exists within the US.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.
12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.
08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.
07.04.2016 Pfizer and Allergan have called off their merger, cancelling plans to relocate the US pharma giant to Ireland to avoid US taxation. The US government has put a spoke in Pfizer’s wheels - an unfair move, Allergan says.